\contentsline {chapter}{Glossary}{xii}{section*.4}
\contentsline {chapter}{Acronyms}{xiii}{section*.6}
\contentsline {chapter}{\numberline {1}Introduction}{1}{chapter.1}
\contentsline {section}{\numberline {1.1}Cancer Research in the Post-Genomic Era}{1}{section.1.1}
\contentsline {subsection}{\numberline {1.1.1}Cancer as a Global Health Concern}{2}{subsection.1.1.1}
\contentsline {subsubsection}{\numberline {1.1.1.1}The Genetics and Molecular Biology of Cancers}{3}{subsubsection.1.1.1.1}
\contentsline {subsection}{\numberline {1.1.2}The Human Genome Revolution}{6}{subsection.1.1.2}
\contentsline {subsubsection}{\numberline {1.1.2.1}The First Human Genome Sequence}{6}{subsubsection.1.1.2.1}
\contentsline {subsubsection}{\numberline {1.1.2.2}Impact of Genomics}{7}{subsubsection.1.1.2.2}
\contentsline {subsection}{\numberline {1.1.3}Technologies to Enable Genetics Research}{7}{subsection.1.1.3}
\contentsline {subsubsection}{\numberline {1.1.3.1}DNA Sequencing and Genotyping Technologies}{7}{subsubsection.1.1.3.1}
\contentsline {subsubsection}{\numberline {1.1.3.2}Microarrays and Quantitative Technologies}{8}{subsubsection.1.1.3.2}
\contentsline {subsubsection}{\numberline {1.1.3.3}Massively Parallel ``Next Generation'' Sequencing}{9}{subsubsection.1.1.3.3}
\contentsline {subsubsubsection}{\numberline {1.1.3.3.1}Molecular Profiling with Genomics Technology}{11}{subsubsubsection.1.1.3.3.1}
\contentsline {subsubsubsection}{\numberline {1.1.3.3.2}Sequencing Technologies}{11}{subsubsubsection.1.1.3.3.2}
\contentsline {subsubsection}{\numberline {1.1.3.4}Bioinformatics as Interdisciplinary Genomic Analysis}{12}{subsubsection.1.1.3.4}
\contentsline {subsection}{\numberline {1.1.4}Follow-up Large-Scale Genomics Projects}{13}{subsection.1.1.4}
\contentsline {subsection}{\numberline {1.1.5}Cancer Genomes}{14}{subsection.1.1.5}
\contentsline {subsubsection}{\numberline {1.1.5.1}The Cancer Genome Atlas Project}{15}{subsubsection.1.1.5.1}
\contentsline {subsubsubsection}{\numberline {1.1.5.1.1}Findings from Cancer Genomes}{15}{subsubsubsection.1.1.5.1.1}
\contentsline {subsubsubsection}{\numberline {1.1.5.1.2}Genomic Comparisons Across Cancer Tissues}{17}{subsubsubsection.1.1.5.1.2}
\contentsline {subsubsubsection}{\numberline {1.1.5.1.3}Cancer Genomic Data Resources}{18}{subsubsubsection.1.1.5.1.3}
\contentsline {subsection}{\numberline {1.1.6}Genomic Cancer Medicine}{18}{subsection.1.1.6}
\contentsline {subsubsection}{\numberline {1.1.6.1}Cancer Genes and Driver Mutations}{18}{subsubsection.1.1.6.1}
\contentsline {subsubsection}{\numberline {1.1.6.2}Personalised or Precision Cancer Medicine}{19}{subsubsection.1.1.6.2}
\contentsline {subsubsubsection}{\numberline {1.1.6.2.1}Molecular Diagnostics and Pan-Cancer Medicine}{20}{subsubsubsection.1.1.6.2.1}
\contentsline {subsubsection}{\numberline {1.1.6.3}Targeted Therapeutics and Pharmacogenomics}{21}{subsubsection.1.1.6.3}
\contentsline {subsubsubsection}{\numberline {1.1.6.3.1}Targeting Oncogenic Driver Mutations}{21}{subsubsubsection.1.1.6.3.1}
\contentsline {subsubsection}{\numberline {1.1.6.4}Systems and Network Biology}{22}{subsubsection.1.1.6.4}
\contentsline {subsubsubsection}{\numberline {1.1.6.4.1} Network Medicine, and Polypharmacology}{24}{subsubsubsection.1.1.6.4.1}
\contentsline {section}{\numberline {1.2}A Synthetic Lethal Approach to Cancer Medicine}{25}{section.1.2}
\contentsline {subsection}{\numberline {1.2.1}Synthetic Lethal Genetic Interactions}{26}{subsection.1.2.1}
\contentsline {subsection}{\numberline {1.2.2}Synthetic Lethal Concepts in Genetics}{26}{subsection.1.2.2}
\contentsline {subsection}{\numberline {1.2.3}Studies of Synthetic Lethality}{27}{subsection.1.2.3}
\contentsline {subsubsection}{\numberline {1.2.3.1}Synthetic Lethal Pathways and Networks}{28}{subsubsection.1.2.3.1}
\contentsline {subsubsubsection}{\numberline {1.2.3.1.1}Evolution of Synthetic Lethality}{29}{subsubsubsection.1.2.3.1.1}
\contentsline {subsection}{\numberline {1.2.4}Synthetic Lethal Concepts in Cancer}{29}{subsection.1.2.4}
\contentsline {subsection}{\numberline {1.2.5}Clinical Impact of Synthetic Lethality in Cancer}{31}{subsection.1.2.5}
\contentsline {subsection}{\numberline {1.2.6}High{}-throughput Screening for Synthetic Lethality}{33}{subsection.1.2.6}
\contentsline {subsubsection}{\numberline {1.2.6.1}Synthetic Lethal Screens}{34}{subsubsection.1.2.6.1}
\contentsline {subsection}{\numberline {1.2.7}Computational Prediction of Synthetic Lethality}{37}{subsection.1.2.7}
\contentsline {subsubsection}{\numberline {1.2.7.1}Bioinformatics Approaches to Genetic Interactions}{37}{subsubsection.1.2.7.1}
\contentsline {subsubsection}{\numberline {1.2.7.2}Comparative Genomics}{38}{subsubsection.1.2.7.2}
\contentsline {subsubsection}{\numberline {1.2.7.3}Analysis and Modelling of Protein Data}{41}{subsubsection.1.2.7.3}
\contentsline {subsubsection}{\numberline {1.2.7.4}Differential Gene Expression}{43}{subsubsection.1.2.7.4}
\contentsline {subsubsection}{\numberline {1.2.7.5}Data Mining and Machine Learning}{44}{subsubsection.1.2.7.5}
\contentsline {subsubsection}{\numberline {1.2.7.6}Bimodality}{47}{subsubsection.1.2.7.6}
\contentsline {subsubsection}{\numberline {1.2.7.7}Rationale for Further Development}{48}{subsubsection.1.2.7.7}
\contentsline {section}{\numberline {1.3}E-cadherin as a Synthetic Lethal Target}{48}{section.1.3}
\contentsline {subsection}{\numberline {1.3.1}The \textit {CDH1} gene and it's Biological Functions}{48}{subsection.1.3.1}
\contentsline {subsubsection}{\numberline {1.3.1.1}Cytoskeleton}{49}{subsubsection.1.3.1.1}
\contentsline {subsubsection}{\numberline {1.3.1.2}Extracellular and Tumour Micro-Environment}{49}{subsubsection.1.3.1.2}
\contentsline {subsubsection}{\numberline {1.3.1.3}Cell-Cell Adhesion and Signalling}{49}{subsubsection.1.3.1.3}
\contentsline {subsection}{\numberline {1.3.2}\textit {CDH1} as a Tumour (and Invasion) Suppressor}{50}{subsection.1.3.2}
\contentsline {subsubsection}{\numberline {1.3.2.1}Breast Cancers and Invasion}{50}{subsubsection.1.3.2.1}
\contentsline {subsection}{\numberline {1.3.3}Hereditary Diffuse Gastric Cancer and Lobular Breast Cancer}{50}{subsection.1.3.3}
\contentsline {subsection}{\numberline {1.3.4}Somatic Mutations}{52}{subsection.1.3.4}
\contentsline {subsubsection}{\numberline {1.3.4.1}Mutation Rate}{52}{subsubsection.1.3.4.1}
\contentsline {subsubsection}{\numberline {1.3.4.2}Co-occurring Mutations}{52}{subsubsection.1.3.4.2}
\contentsline {subsection}{\numberline {1.3.5}Models of \textit {CDH1} loss in cell lines}{53}{subsection.1.3.5}
\contentsline {section}{\numberline {1.4}Summary and Research Direction of Thesis}{54}{section.1.4}
\contentsline {chapter}{\numberline {2}Methods and Resources}{58}{chapter.2}
\contentsline {section}{\numberline {2.1}Bioinformatics Resources for Genomics Research}{58}{section.2.1}
\contentsline {subsection}{\numberline {2.1.1}Public Data and Software Packages}{58}{subsection.2.1.1}
\contentsline {subsubsection}{\numberline {2.1.1.1}Cancer Genome Atlas Data}{59}{subsubsection.2.1.1.1}
\contentsline {subsubsection}{\numberline {2.1.1.2}Reactome and Annotation Data}{60}{subsubsection.2.1.1.2}
\contentsline {section}{\numberline {2.2}Data Handling}{61}{section.2.2}
\contentsline {subsection}{\numberline {2.2.1}Normalisation}{61}{subsection.2.2.1}
\contentsline {subsection}{\numberline {2.2.2}Sample Triage}{61}{subsection.2.2.2}
\contentsline {subsection}{\numberline {2.2.3}Metagenes and the Singular Value Decomposition}{63}{subsection.2.2.3}
\contentsline {subsubsection}{\numberline {2.2.3.1}Candidate Triage and Integration with Screen Data}{63}{subsubsection.2.2.3.1}
\contentsline {section}{\numberline {2.3}Techniques}{64}{section.2.3}
\contentsline {subsection}{\numberline {2.3.1}Statistical Procedures and Tests}{64}{subsection.2.3.1}
\contentsline {subsection}{\numberline {2.3.2}Gene Set Over-representation Analysis}{65}{subsection.2.3.2}
\contentsline {subsection}{\numberline {2.3.3}Clustering}{66}{subsection.2.3.3}
\contentsline {subsection}{\numberline {2.3.4}Heatmap}{66}{subsection.2.3.4}
\contentsline {subsection}{\numberline {2.3.5}Modeling and Simulations}{66}{subsection.2.3.5}
\contentsline {subsubsection}{\numberline {2.3.5.1}Receiver Operating Characteristic (Performance)}{67}{subsubsection.2.3.5.1}
\contentsline {subsection}{\numberline {2.3.6}Resampling Analysis}{68}{subsection.2.3.6}
\contentsline {section}{\numberline {2.4}Pathway Structure Methods}{69}{section.2.4}
\contentsline {subsection}{\numberline {2.4.1}Network and Graph Analysis}{69}{subsection.2.4.1}
\contentsline {subsection}{\numberline {2.4.2}Sourcing Graph Structure Data}{70}{subsection.2.4.2}
\contentsline {subsection}{\numberline {2.4.3}Constructing Pathway Subgraphs}{70}{subsection.2.4.3}
\contentsline {subsection}{\numberline {2.4.4}Network Analysis Metrics}{70}{subsection.2.4.4}
\contentsline {section}{\numberline {2.5}Implementation}{71}{section.2.5}
\contentsline {subsection}{\numberline {2.5.1}Computational Resources and Linux Utilities}{71}{subsection.2.5.1}
\contentsline {subsection}{\numberline {2.5.2}R Language and Packages}{73}{subsection.2.5.2}
\contentsline {subsection}{\numberline {2.5.3}High Performance and Parallel Computing}{75}{subsection.2.5.3}
\contentsline {chapter}{\numberline {3}Methods Developed During Thesis}{77}{chapter.3}
\contentsline {section}{\numberline {3.1}A Synthetic Lethal Detection Methodology}{77}{section.3.1}
\contentsline {section}{\numberline {3.2}Synthetic Lethal Simulation and Modelling}{80}{section.3.2}
\contentsline {subsection}{\numberline {3.2.1}A Model of Synthetic Lethality in Expression Data}{80}{subsection.3.2.1}
\contentsline {subsection}{\numberline {3.2.2}Simulation Procedure}{84}{subsection.3.2.2}
\contentsline {section}{\numberline {3.3}Detecting Simulated Synthetic Lethal Partners}{87}{section.3.3}
\contentsline {subsection}{\numberline {3.3.1}Binomial Simulation of Synthetic lethality}{87}{subsection.3.3.1}
\contentsline {subsection}{\numberline {3.3.2}Multivariate Normal Simulation of Synthetic lethality}{89}{subsection.3.3.2}
\contentsline {subsubsection}{\numberline {3.3.2.1}Multivariate Normal Simulation with Correlated Genes}{92}{subsubsection.3.3.2.1}
\contentsline {subsubsection}{\numberline {3.3.2.2}Specificity with Query-Correlated Pathways}{99}{subsubsection.3.3.2.2}
\contentsline {subsubsection}{\numberline {3.3.2.3}Importance of Directional Testing}{99}{subsubsection.3.3.2.3}
\contentsline {section}{\numberline {3.4}Graph Structure Methods}{101}{section.3.4}
\contentsline {subsection}{\numberline {3.4.1}Upstream and Downstream Gene Detection}{101}{subsection.3.4.1}
\contentsline {subsubsection}{\numberline {3.4.1.1}Permutation Analysis for Statistical Significance}{102}{subsubsection.3.4.1.1}
\contentsline {subsubsection}{\numberline {3.4.1.2}Hierarchy Based on Biological Context}{103}{subsubsection.3.4.1.2}
\contentsline {subsection}{\numberline {3.4.2}Simulating Gene Expression from Graph Structures}{104}{subsection.3.4.2}
\contentsline {section}{\numberline {3.5}Customised Functions and Packages Developed}{108}{section.3.5}
\contentsline {subsection}{\numberline {3.5.1}Synthetic Lethal Interaction Prediction Tool}{108}{subsection.3.5.1}
\contentsline {subsection}{\numberline {3.5.2}Data Visualisation}{109}{subsection.3.5.2}
\contentsline {subsection}{\numberline {3.5.3}Extensions to the iGraph Package}{112}{subsection.3.5.3}
\contentsline {subsubsection}{\numberline {3.5.3.1}Sampling Simulated Data from Graph Structures}{112}{subsubsection.3.5.3.1}
\contentsline {subsubsection}{\numberline {3.5.3.2}Plotting Directed Graph Structures}{112}{subsubsection.3.5.3.2}
\contentsline {subsubsection}{\numberline {3.5.3.3}Computing Information Centrality}{113}{subsubsection.3.5.3.3}
\contentsline {subsubsection}{\numberline {3.5.3.4}Testing Pathway Structure with Permutation Testing}{113}{subsubsection.3.5.3.4}
\contentsline {subsubsection}{\numberline {3.5.3.5}Metapackage to Install iGraph Functions}{114}{subsubsection.3.5.3.5}
\contentsline {chapter}{\numberline {4}Synthetic Lethal Analysis of Gene Expression Data}{115}{chapter.4}
\contentsline {section}{\numberline {4.1}Synthetic lethal genes in breast cancer}{116}{section.4.1}
\contentsline {subsection}{\numberline {4.1.1}Synthetic lethal pathways in breast cancer}{118}{subsection.4.1.1}
\contentsline {subsection}{\numberline {4.1.2}Expression profiles of synthetic lethal partners}{119}{subsection.4.1.2}
\contentsline {subsubsection}{\numberline {4.1.2.1}Subgroup pathway analysis}{122}{subsubsection.4.1.2.1}
\contentsline {section}{\numberline {4.2}Comparison of synthetic lethal gene candidates}{125}{section.4.2}
\contentsline {subsection}{\numberline {4.2.1}Comparison with siRNA screen candidates}{125}{subsection.4.2.1}
\contentsline {subsection}{\numberline {4.2.2}Comparison with correlation}{126}{subsection.4.2.2}
\contentsline {subsection}{\numberline {4.2.3}Comparison with viability}{127}{subsection.4.2.3}
\contentsline {subsection}{\numberline {4.2.4}Comparison with secondary siRNA screen candidates}{130}{subsection.4.2.4}
\contentsline {subsection}{\numberline {4.2.5}Comparison of screen at pathway level}{130}{subsection.4.2.5}
\contentsline {subsubsection}{\numberline {4.2.5.1}Resampling of genes for pathway enrichment}{132}{subsubsection.4.2.5.1}
\contentsline {section}{\numberline {4.3}Metagene Analysis}{138}{section.4.3}
\contentsline {subsection}{\numberline {4.3.1}Pathway expression}{138}{subsection.4.3.1}
\contentsline {subsection}{\numberline {4.3.2}Somatic mutation}{141}{subsection.4.3.2}
\contentsline {subsection}{\numberline {4.3.3}Synthetic lethal metagenes}{142}{subsection.4.3.3}
\contentsline {section}{\numberline {4.4}Replication in stomach cancer}{144}{section.4.4}
\contentsline {subsection}{\numberline {4.4.1}Synthetic Lethal Genes and Pathways}{144}{subsection.4.4.1}
\contentsline {subsection}{\numberline {4.4.2}Synthetic Lethal Expression Profiles}{146}{subsection.4.4.2}
\contentsline {subsection}{\numberline {4.4.3}Comparison to Primary Screen}{148}{subsection.4.4.3}
\contentsline {subsubsection}{\numberline {4.4.3.1}Resampling Analysis}{149}{subsubsection.4.4.3.1}
\contentsline {subsection}{\numberline {4.4.4}Metagene Analysis}{150}{subsection.4.4.4}
\contentsline {section}{\numberline {4.5}Global Synthetic Lethality}{150}{section.4.5}
\contentsline {subsection}{\numberline {4.5.1}Hub Genes}{152}{subsection.4.5.1}
\contentsline {subsection}{\numberline {4.5.2}Hub Pathways}{153}{subsection.4.5.2}
\contentsline {section}{\numberline {4.6}Replication in cell line encyclopaedia}{154}{section.4.6}
\contentsline {section}{\numberline {4.7}Discussion}{157}{section.4.7}
\contentsline {subsection}{\numberline {4.7.1}Strengths of the SLIPT Methodology}{157}{subsection.4.7.1}
\contentsline {subsection}{\numberline {4.7.2}Syntheic Lethal Pathways for E-cadherin}{158}{subsection.4.7.2}
\contentsline {subsection}{\numberline {4.7.3}Replication and Validation}{160}{subsection.4.7.3}
\contentsline {subsubsection}{\numberline {4.7.3.1}Integration with siRNA Screening}{160}{subsubsection.4.7.3.1}
\contentsline {subsubsection}{\numberline {4.7.3.2}Replication across Tissues and Cell lines}{160}{subsubsection.4.7.3.2}
\contentsline {section}{\numberline {4.8}Summary}{161}{section.4.8}
\contentsline {paragraph}{Aims}{163}{section*.42}
\contentsline {paragraph}{Summary}{163}{section*.43}
\contentsline {chapter}{\numberline {5}Synthetic Lethal Pathway Structure}{164}{chapter.5}
\contentsline {section}{\numberline {5.1}Synthetic Lethal Genes in Reactome Pathways}{165}{section.5.1}
\contentsline {subsection}{\numberline {5.1.1}The PI3K/AKT Pathway}{165}{subsection.5.1.1}
\contentsline {subsection}{\numberline {5.1.2}The Extracellular Matrix}{167}{subsection.5.1.2}
\contentsline {subsection}{\numberline {5.1.3}G Protein Coupled Receptors}{170}{subsection.5.1.3}
\contentsline {subsection}{\numberline {5.1.4}Gene Regulation and Translation}{171}{subsection.5.1.4}
\contentsline {section}{\numberline {5.2}Network Analysis of Synthetic Lethal Genes}{172}{section.5.2}
\contentsline {subsection}{\numberline {5.2.1}Gene Connectivity and Vertex Degree}{172}{subsection.5.2.1}
\contentsline {subsection}{\numberline {5.2.2}Gene Importance and Centrality}{174}{subsection.5.2.2}
\contentsline {subsubsection}{\numberline {5.2.2.1}Information Centrality}{174}{subsubsection.5.2.2.1}
\contentsline {subsubsection}{\numberline {5.2.2.2}PageRank Centrality}{176}{subsubsection.5.2.2.2}
\contentsline {section}{\numberline {5.3}Relationships between Synthetic Lethal Genes}{177}{section.5.3}
\contentsline {subsection}{\numberline {5.3.1}Hierarchical Pathway Structure}{177}{subsection.5.3.1}
\contentsline {subsubsection}{\numberline {5.3.1.1}Contextual Hierarchy of PI3K}{177}{subsubsection.5.3.1.1}
\contentsline {subsubsection}{\numberline {5.3.1.2}Testing Contextual Hierarchy of Synthetic Lethal Genes}{178}{subsubsection.5.3.1.2}
\contentsline {subsection}{\numberline {5.3.2}Upstream or Downstream Synthetic Lethality}{181}{subsection.5.3.2}
\contentsline {subsubsection}{\numberline {5.3.2.1}Measuring Structure of Candidates within PI3K}{181}{subsubsection.5.3.2.1}
\contentsline {subsubsection}{\numberline {5.3.2.2}Resampling for Synthetic Lethal Pathway Structure}{183}{subsubsection.5.3.2.2}
\contentsline {section}{\numberline {5.4}Discussion}{185}{section.5.4}
\contentsline {section}{\numberline {5.5}Summary}{187}{section.5.5}
\contentsline {paragraph}{Aims}{189}{section*.28}
\contentsline {paragraph}{Summary}{189}{section*.29}
\contentsline {chapter}{\numberline {6}Simulation and Modeling of Synthetic Lethal Pathways}{192}{chapter.6}
\contentsline {section}{\numberline {6.1}Comparing methods}{193}{section.6.1}
\contentsline {subsection}{\numberline {6.1.1}Performance of SLIPT and $\chi ^2$ across Quantiles}{194}{subsection.6.1.1}
\contentsline {subsubsection}{\numberline {6.1.1.1}Correlated Query Genes affects Specificity}{197}{subsubsection.6.1.1.1}
\contentsline {subsection}{\numberline {6.1.2}Alternative Synthetic Lethal Detection Strategies}{199}{subsection.6.1.2}
\contentsline {subsubsection}{\numberline {6.1.2.1}Correlation for Synthetic Lethal Detection}{200}{subsubsection.6.1.2.1}
\contentsline {subsubsection}{\numberline {6.1.2.2}Testing for Bimodality with BiSEp}{201}{subsubsection.6.1.2.2}
\contentsline {section}{\numberline {6.2}Simulations with Graph Structures}{203}{section.6.2}
\contentsline {subsection}{\numberline {6.2.1}Performance over a Graph Structure}{204}{subsection.6.2.1}
\contentsline {subsubsection}{\numberline {6.2.1.1}Simple Graph Structures}{204}{subsubsection.6.2.1.1}
\contentsline {subsubsection}{\numberline {6.2.1.2}Constructed Graph Structures}{206}{subsubsection.6.2.1.2}
\contentsline {subsection}{\numberline {6.2.2}Performance with Inhibitions}{210}{subsection.6.2.2}
\contentsline {subsection}{\numberline {6.2.3}Synthetic Lethality across Graph Structures}{216}{subsection.6.2.3}
\contentsline {subsection}{\numberline {6.2.4}Performance within a Simulated Human Genome}{220}{subsection.6.2.4}
\contentsline {section}{\numberline {6.3}Simulations over pathway-based graphs}{226}{section.6.3}
\contentsline {subsection}{\numberline {6.3.1}Pathway Structures in a Simulated Human Genome}{228}{subsection.6.3.1}
\contentsline {section}{\numberline {6.4}Discussion}{231}{section.6.4}
\contentsline {subsection}{\numberline {6.4.1}Simulation Procedure}{231}{subsection.6.4.1}
\contentsline {subsection}{\numberline {6.4.2}Design and Performance of SLIPT}{232}{subsection.6.4.2}
\contentsline {subsection}{\numberline {6.4.3}Simulations from Graph Structures}{234}{subsection.6.4.3}
\contentsline {section}{\numberline {6.5}Summary}{235}{section.6.5}
\contentsline {paragraph}{Aims}{237}{section*.30}
\contentsline {paragraph}{Summary}{237}{section*.31}
\contentsline {chapter}{\numberline {7}Discussion}{238}{chapter.7}
\contentsline {section}{\numberline {7.1}Significance}{238}{section.7.1}
\contentsline {section}{\numberline {7.2}Future Directions}{239}{section.7.2}
\contentsline {section}{\numberline {7.3}Conclusion}{240}{section.7.3}
\contentsline {paragraph}{Aims}{241}{section*.124}
\contentsline {paragraph}{Summary}{242}{section*.125}
\contentsline {chapter}{\numberline {8}Conclusion}{244}{chapter.8}
\contentsline {chapter}{\hbox to\@tempdima {\hfil }References}{245}{section*.29}
\contentsline {chapter}{\numberline {A}Sample Quality}{271}{appendix.A}
\contentsline {section}{\numberline {A.1}Sample Correlation}{271}{section.A.1}
\contentsline {section}{\numberline {A.2}Replicate Samples in TCGA Breast}{274}{section.A.2}
\contentsline {chapter}{\numberline {B}Software Used for Thesis}{278}{appendix.B}
\contentsline {chapter}{\numberline {C}Secondary Screen Data}{287}{appendix.C}
\contentsline {chapter}{\numberline {D}Mutation Analysis in Breast Cancer}{289}{appendix.D}
\contentsline {section}{\numberline {D.1}Synthetic Lethal Genes and Pathways}{289}{section.D.1}
\contentsline {section}{\numberline {D.2}Synthetic Lethal Expression Profiles}{292}{section.D.2}
\contentsline {section}{\numberline {D.3}Comparison to Primary Screen}{295}{section.D.3}
\contentsline {subsection}{\numberline {D.3.1}Resampling Analysis}{297}{subsection.D.3.1}
\contentsline {section}{\numberline {D.4}Compare SLIPT genes}{299}{section.D.4}
\contentsline {section}{\numberline {D.5}Metagene Analysis}{301}{section.D.5}
\contentsline {section}{\numberline {D.6}Mutation Variation}{302}{section.D.6}
\contentsline {subsection}{\numberline {D.6.1}Mutation Frequency}{302}{subsection.D.6.1}
\contentsline {subsection}{\numberline {D.6.2}PI3K Mutation Expression}{303}{subsection.D.6.2}
\contentsline {chapter}{\numberline {E}Metagene Expression Profiles}{306}{appendix.E}
\contentsline {chapter}{\numberline {F}Stomach Expression Analysis}{312}{appendix.F}
\contentsline {section}{\numberline {F.1}Synthetic Lethal Genes and Pathways}{312}{section.F.1}
\contentsline {section}{\numberline {F.2}Comparison to Primary Screen}{315}{section.F.2}
\contentsline {subsection}{\numberline {F.2.1}Resampling Analysis}{317}{subsection.F.2.1}
\contentsline {section}{\numberline {F.3}Metagene Analysis}{319}{section.F.3}
\contentsline {chapter}{\numberline {G}Stomach Mutation Analysis}{320}{appendix.G}
\contentsline {section}{\numberline {G.1}Synthetic Lethal Genes and Pathways}{320}{section.G.1}
\contentsline {section}{\numberline {G.2}Synthetic Lethal Expression Profiles}{323}{section.G.2}
\contentsline {section}{\numberline {G.3}Comparison to Primary Screen}{326}{section.G.3}
\contentsline {subsection}{\numberline {G.3.1}Resampling Analysis}{328}{subsection.G.3.1}
\contentsline {section}{\numberline {G.4}Metagene Analysis}{330}{section.G.4}
\contentsline {chapter}{\numberline {H}Global Synthetic Lethality in Stomach Cancer}{331}{appendix.H}
\contentsline {section}{\numberline {H.1}Hub Genes}{333}{section.H.1}
\contentsline {section}{\numberline {H.2}Hub Pathways}{334}{section.H.2}
\contentsline {chapter}{\numberline {I}Replication in cell line encyclopaedia}{335}{appendix.I}
\contentsline {chapter}{\numberline {J}Synthetic Lethal Genes in Pathways}{340}{appendix.J}
\contentsline {chapter}{\numberline {K}Pathway Connectivity for Mutation SLIPT}{348}{appendix.K}
\contentsline {chapter}{\numberline {L}Information Centrality for Gene Essentiality}{352}{appendix.L}
\contentsline {chapter}{\numberline {M}Pathway Structure for Mutation SLIPT}{355}{appendix.M}
